Aptevo Therapeutics (APVO) Change in Accured Expenses (2015 - 2026)

Aptevo Therapeutics has reported Change in Accured Expenses for 12 years, with the latest figure at -$1.3 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 19.32% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$368000.0 (up 68.89% YoY) and the FY2025 annual result came in at -$157000.0, up 84.56% from the prior year.
• Change in Accured Expenses eased to -$1.3 million in Q1 2026 per APVO's latest filing, from $434000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $1.1 million in Q2 2023 and troughed at -$1.4 million in Q2 2022.
• A 5-year average of -$138411.8 and a median of -$76000.0 in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses sank 3345.24% in 2022, then jumped 710.53% in 2024.
• Over 5 years, Change in Accured Expenses stood at $989000.0 in 2022, then sank by 60.67% to $389000.0 in 2023, then declined by 16.71% to $324000.0 in 2024, then surged by 33.95% to $434000.0 in 2025, then sank by 400.23% to -$1.3 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$1.3 million, $434000.0, and $724000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.